IsoRay, Inc. (NYSEMKT:ISR) net income growth from the same quarter one year ago has exceeded that of the S&P 500 and the Biotechnology industry average. The net income increased by 19.7% when compared to the same quarter one year prior, going from -$1.16 million to -$0.93 million. IsoRay, Inc. (NYSEMKT:ISR) shares after opening at $3.01 moved to $3.47 on last trade day and at the end of the day closed at $3.09. Company price to sales ratio in past twelve months was calculated as 36.26 and price to cash ratio as 37.91. IsoRay, Inc. (NYSEMKT:ISR) showed a positive weekly performance of 31.49%.
CytRx Corporation (NASDAQ:CYTR) on Apr. 2 said that positive preclinical results from an in vivo study of aldoxorubicin in an animal model of glioblastoma will be presented at the American Association for Cancer Research Annual Meeting being held April 5-9, 2014 in San Diego, CA.
CytRx Corporation (NASDAQ:CYTR) shares advanced 3.67% in last trading session and ended the day on $3.95. CYTR return on equity ratio is recorded as -287.90% and its return on assets is -146.40%. CytRx Corporation (NASDAQ:CYTR) yearly performance is 50.19%.
Shares of Response Genetics Inc. (NASDAQ:RGDX) jumped 18 percent on Thursday after the cancer diagnostic test company signed agreements with six additional health plans and two large health care groups. Response Genetics, Inc. (NASDAQ:RGDX) shares moved up 18.33% in last trading session and was closed at $1.42, while trading in range of $1.34 – $1.56. Response Genetics, Inc. (NASDAQ:RGDX) year to date (YTD) performance is 22.41%.
Sanofi (ADR) (NYSE:SNY) Announces FDA Has Expanded Age Indication of Adacel® Tdap Vaccine to Include Persons 10 Years of Age. Sanofi SA (ADR) (NYSE:SNY) weekly performance is 0.56%. On last trading day company shares ended up $52.04. Sanofi SA (ADR) (NYSE:SNY) distance from 50-day simple moving average (SMA50) is 3.02%. Analysts mean target price for the company is $56.21.